|Day's Range||2,694.59 - 2,741.38|
|52 Week Range||2,322.25 - 2,872.87|
Market recap for Monday March 19
Yahoo Finance’s Seana Smith on the tech-driving market selloff, Facebook’s troubles, Uber halting self-driving vehicle tests and Trump’s executive order banning Venezuelan cryptocurrencies in the U.S.
It was rough sailing for many stocks Monday, but several leaders in or near buy zones weathered the storm.: Charles Schwab, ASML, First Solar, Weibo and TAL Education.
The Dow, S&P 500 and the tech-heavy Nasdaq declined on Monday as Facebook finds itself in hot water over reports that as many as 50 million of its users may have had their data compromised.
The Dow Jones Industrial Average dropped 330 points today, but the real damage was in the Nasdaq thanks to Facebook (FB), which suffered its largest one-day drop since 2014. •...and explain why Exact Science's naming of Harry Connick Jr. as a spokesperson caused its shares to tumble. The Nasdaq Composite slumped 1.8% to 7344.24.
The stock market’s glory days may be behind us. At least, that’s the prognosis of one prominent Wall Street strategist who believes January may have been the market’s peak and the remainder of the year ...
Signet Jewelers (SIG) popped to the top of the S&P 500 on Monday, a stark contrast to its plunge last week. Last week Signet sank on its disappointing earnings report, but some analysts have been willing to defend the stock--to an extent. Cowen & Co.'s Oliver Chen recently reiterated a Market Perform, writing that he "commend[s] management for facing profound issues which could otherwise yield long-term damage," and CFRA's Victor Ahluwalia reiterated a Hold rating on the stock today, although he shaved $16 off his price target, to $41, citing "reduced earnings visibility and restructuring uncertainties." Signet was also benefiting from a less-bad day for retail overall, as other winners included Macy's (M), Kohl's (KSS), and Tiffany (TIF). Signet is down 30.2% year to date and off 42.2% in the past 12 months.
On a day stocks fell hard, Micro Focus plummeted on a worsening outlook for software sales, and Heron Therapeutics soared after reporting strong results from a drug trial.